Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection

NACompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

September 6, 2017

Study Completion Date

September 6, 2017

Conditions
Hemorrhage
Interventions
PROCEDURE

BioFoam® Surgical Matrix

Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.

OTHER

Conservative hemostasis

Complete hemostasis will be achieved without the use of topical agents

Trial Locations (1)

01307

Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, TU Dresden, Germany, Dresden

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CryoLife, Inc.

INDUSTRY

lead

Technische Universität Dresden

OTHER

NCT02612220 - Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection | Biotech Hunter | Biotech Hunter